Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca's Bydureon BCise Gets U.S. Approval For Type 2 Diabetes in Pediatric Patients

07/23/2021 | 06:26am EDT

By Michael Dabaie

AstraZeneca said its Bydureon BCise, or exenatide extended-release, was approved in the U.S. for the treatment of type 2 diabetes in pediatric patients ages 10 years and older.

The U.S. Food and Drug Administration approval was supported by the results of the BCB114 Phase III trial in youth with type 2 diabetes. which showed on top of standard of care exenatide extended-release significantly improved glycemic control compared to placebo in pediatrics.

Bydureon BCise was first approved in the U.S. in October 2017 as a once-weekly single-dose autoinjector device to improve glycemic control for adults with type 2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines in addition to diet and exercise. It was also approved for use in the European Union in August 2018.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

07-23-21 0826ET

All news about ASTRAZENECA PLC
11:01aEuropean ADRs Move Higher in Monday Trading
MT
08:51aASTRAZENECA : SVB Leerink Adjusts AstraZeneca's PT to $73 from $71, Keeps Outperform Ratin..
MT
07:36aASTRAZENECA : Biohaven's neurological disorder drug candidate fails study
RE
05:55aASTRAZENECA : EU Commission proposes extending vaccine export-control scheme
RE
05:17aSHIELD THERAPEUTICS : Names New Chief Medical Officer
MT
04:43aASTRAZENECA : EU Commission proposes extending vaccine export-control scheme
RE
04:00aASTRAZENECA : Small study shows antibody growth from AstraZeneca, Sputnik Light COVID-19 v..
RE
02:40aASTRAZENECA : Pfizer Deny Spat Following Lawyer's Leaked Health Threat Accusation
MT
02:12aASTRAZENECA : COVID-19 and RSV presentations at IDWeek 2021 will showcase scientific progr..
PU
01:21aASTRAZENECA : Pfizer's comments on rival vaccine posed 'health threat'
AQ
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 471 M - -
Net income 2021 5 006 M - -
Net Debt 2021 24 250 M - -
P/E ratio 2021 24,0x
Yield 2021 3,29%
Capitalization 133 B 182 B -
EV / Sales 2021 4,43x
EV / Sales 2022 3,57x
Nbr of Employees 76 100
Free-Float 96,3%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 85,67 $
Average target price 136,24 $
Spread / Average Target 59,0%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC20.77%187 304
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.19.37%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037